Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
01
03
2022
accepted:
27
06
2022
revised:
16
06
2022
pubmed:
9
7
2022
medline:
7
10
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
Cryopreservation was recommended to ensure continuity in allogeneic hematopoietic progenitor cells (HPC) transplantation during the COVID-19 pandemic. Several groups have shown no impact on clinical outcomes for patients who underwent HPC transplantation with cryopreserved products during the first months of this pandemic. However, concerns about quality control attributes after cryopreservation have been raised. We investigated, in 155 allogeneic peripheral blood cryopreserved HPC, leukocytapheresis characteristics influencing viable CD34
Identifiants
pubmed: 35804055
doi: 10.1038/s41409-022-01750-2
pii: 10.1038/s41409-022-01750-2
pmc: PMC9264299
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1531-1538Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell cryopreservation been given the “cold shoulder”? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transpl. 2006;38:399–405.
doi: 10.1038/sj.bmt.1705462
Schmidt AH, Buk D, Platz A, van den Brink MRM. Cryopreservation for All Is No Option in Unrelated Stem Cell Transplantation. Comment on Dholaria B, et al. Securing the Graft During Pandemic: Are We Ready for Cryopreservation for All? Biol Blood Marrow Transpl. 2020;26:e145–6.
doi: 10.1016/j.bbmt.2020.04.009
Fernandez-Sojo J, Azqueta C, Valdivia E, Martorell L, Medina-Boronat L, Martinez-Llonch N, et al. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Bone Marrow Transpl. 2021;56:2489–96.
doi: 10.1038/s41409-021-01367-x
Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transpl. 2007;13:1233–43.
doi: 10.1016/j.bbmt.2007.07.003
Update of October 5th, 2020, of the guidelines of the Spanish National Transplant Organization (Spain Ministry of Health, Consumer Affairs and Social Welfare) about the impact of SARS-CoV-2 and COVID-19 on donation and transplantation, reference BV-ES-20200122-11. http://www.ont.es/infesp/Paginas/COVID-19.aspx .
Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) regarding the situation generated by the COVID-19 pandemic. 2020 https://www.ebmt.org/sites/default/files/2020-03/EBMT%20COVID19%20guidelines%20v.4.3%20%282020-03-23%29.pdf
Recommendations of the World Marrow Donor Association (WMDA) regarding donor medical suitability in the situation generated by the COVID-19 pandemic 2021. https://share.wmda.info/display/DMSR/Coronavirus+-+COVID-19#/
Maurer K, Kim HT, Kuczmarski TM, Garrity HM, Weber A, Reynolds CG, et al. Impact of Cryopreservation and Transit Times of Allogeneic Grafts on Hematopoietic and Immune Reconstitution. Blood Adv. 2021;5:5140–9.
doi: 10.1182/bloodadvances.2021005139
Abstracts from the 2021 ASH Annual Meeting and Exposition. Devine S. 2846;2021.
Purtill D, Hutchins C, Kennedy G, McClean A, Fraser C, Shaw PJ, et al. Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. Transpl Cell Ther. 2021;27:1022.e1–e6.
doi: 10.1016/j.jtct.2021.09.012
Valentini CG, Chiusolo P, Bianchi M, Metafuni E, Orlando N, Giammarco S, et al. Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. Cytotherapy 2021;23:635–40.
doi: 10.1016/j.jcyt.2020.12.001
Purtill D, Antonenas V, Chiappini P, Tong D, O’Flaherty E, Bajel A, et al. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. Blood Adv. 2020;4:4147–50.
doi: 10.1182/bloodadvances.2020002431
Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011;117:3277–85.
doi: 10.1182/blood-2010-08-300491
Yang H, Acker JP, Cabuhat M, Letcher B, Larrat L, McGann LE. Association of post-thaw viable CD34 þ cells and CFU-GM with time to hematopoietic engraftment. Bone Marrow Transpl. 2005;35:881–7.
doi: 10.1038/sj.bmt.1704926
Lee S, Kim S, Kim H, Baek EJ, Jin H, Kim J, et al. Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation. Vox Sang. 2008;94:146–52.
pubmed: 18028260
Purtill D, Smith K, Devlin S, Meagher R, Tonon J, Lubin M, et al. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood 2014;124:2905–12.
doi: 10.1182/blood-2014-03-566216
Lanza F, Saccardi R, Seghatchian J. New horizons on stem cell cryopreservation through the artificial eyes of CD34 using modern flow cytometry tools. Transfus Apher Sci. 2020;59:102785.
doi: 10.1016/j.transci.2020.102785
Berens C, Heine A, Müller J, Held SA, Mayer K, Brossart P, et al. Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. Cytotherapy 2016;18:1325–31.
doi: 10.1016/j.jcyt.2016.06.014
Fisher V, Khuu H, David-Ocampo V, Byrne K, Pavletic S, Bishop M, et al. Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation. Transfusion 2014;54:1088–92.
doi: 10.1111/trf.12428
Wiercinska E, Schlipfenbacher V, Bug G, Bader P, Verbeek M, Seifried E, et al. Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. J Transl Med. 2021;19:145.
doi: 10.1186/s12967-021-02810-9
Reddy OL, Stroncek DF, Panch SR. Improving CAR T cell therapy by optimizing critical quality attributes. Semin Hematol. 2020;57:33–38.
doi: 10.1053/j.seminhematol.2020.07.005
Yoo KH, Lee SH, Kim HJ, Sung KW, Jung HL, Cho EJ, et al. The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transpl. 2007;39:515–21.
doi: 10.1038/sj.bmt.1705629
Castillo N, Garcia-Cadenas I, Barba P, Martino R, Azqueta C, Ferra C, et al. Post-thaw viable CD45+ cells and clonogenic efficiency are associated with better engraftment and outcomes after single cord blood transplantation in adult patients with malignant disease. Biol Blood Marrow Transpl. 2015;21:2167–72.
doi: 10.1016/j.bbmt.2015.08.016
Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134:517–25.
doi: 10.1111/j.1365-2141.2006.06223.x